Debate continues about the health benefits of marijuana, but recent research suggests that THC could have noteworthy positive effects on brain health.
A team from the University of Texas (UT) San Antonio Long School of Medicine has discovered that THC, the main psychoactive ingredient in marijuana, may defend against the onset of Alzheimer’s disease, particularly when paired with an anti-inflammatory medication called celecoxib.
Celecoxib is typically prescribed for issues such as arthritis and pain relief.
As stated in a UT Health press release, it has been established that THC possesses anti-inflammatory and neuroprotective properties. However, its association with negative impacts on areas like learning and memory has raised concerns.
The combination of THC and anti-inflammatory drugs could potentially allow the benefits while minimizing adverse effects.
In a study published in the journal Aging and Disease, researchers combined low doses of THC extract with celecoxib for daily administration to mice over 30 days.
The treatments were given before any memory-related symptoms emerged, and researchers gauged the effectiveness in preventing or delaying Alzheimer’s disease.
The findings indicated enhancements in cognition, alongside reduced neuroinflammatory markers and brain lesions linked to Alzheimer’s. While THC alone yielded similar results, it also elevated inflammatory signals. In contrast, using the two drugs together did not.
“What really mattered was the behavior. If cognition didn’t improve, the treatment didn’t matter,” remarked Dr. Chu Chen, the study’s lead author and a professor in the Department of Cellular and Integrative Physiology.
Chen’s extensive research has revealed how THC interacts with the brain, shedding light on the challenges of safely using it for neurological conditions.
“Administering THC unexpectedly increases COX-2 in the brain, a factor closely related to memory and learning deficits,” he noted.
Both THC and celecoxib have FDA approval for use in humans, and there’s potential for significant benefits as they move towards clinical trials.
Future research aims to explore whether these drug combinations can delay disease progression or reverse deficits post-symptom onset.
Dr. Paul Safieh, a neurosurgeon and founder of Coaxial Neurosurgical Specialists in New Jersey, described this study as a promising advancement that may greatly benefit patients and their families.
He highlighted the connection between neurocognitive decline and conditions that induce inflammation in the brain, suggesting that combining THC and celecoxib can help mitigate the buildup of beta-amyloid plaques—linked to chronic inflammation and Alzheimer’s—thus potentially slowing disease progression.
With the drugs’ FDA status being viewed as “encouraging,” Safieh expressed hope for upcoming trial results and their implications for treating chronic inflammation in the central nervous system.
